Author

A.C. Roy

Observed name: A. Roy

Institutions: Flinders University, Flinders Medical Centre

Observed institutions: Flinders University, Flinders Medical Centre

OpenAlex ID: A5009578564

LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)

2024 · S. Rao, E. Samalin-Scalzi, et al. · Annals of Oncology · 12

Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer

2026 · S. Rao, E. Samalin-Scalzi, et al. · Annals of Oncology · 3

123MO Survival outcomes in POD1UM-303/InterAACT-2: A phase III study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC)

2025 · S. Rao, E. Samalin-Scalzi, et al. · Immuno-Oncology Technology · 2

266eTiP CHAPTER-GIST-101: A phase I trial of pimitespib and imatinib in patients with gastrointestinal stromal tumors refractory to imatinib

2026 · Y. Kurokawa, Y. Naito, et al. · ESMO rare cancers.

403P First-line anti-EGFR therapy, patient characteristics and survival: Results from South Australian (SA) metastatic colorectal registry (mCRCR)

2022 · T.J. Price, C.S. Karapetis, et al. · Annals of Oncology

Works count: 5

Citation count: 17

H-index: 2

I10-index: 1